Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting
November 11, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...
Galectin Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update
November 09, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Selected to Present at Cavendish Global Health Impact Forum
October 23, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today...
Galectin Therapeutics' GR-MD-02 to be Studied in Combination With Keytruda(R) in Patients With Metastatic Melanoma
October 19, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...
Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference
October 07, 2015 16:08 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02
September 24, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...
Galectin Therapeutics to Present at 2015 Ladenburg Thalmann Healthcare Conference
September 22, 2015 10:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today...
Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis
September 16, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...
Galectin Therapeutics to Participate in Three Investment Conferences in September
September 08, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that...
Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
August 13, 2015 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces...